Kadcyla (ado-trastuzumab) coverage
Customize your policy alerts
Sign up for Anthem Policy CC-0115 alerts
Get alerted when Policy CC-0115 changes without checking for updates manually.
Monitor payer policy activity
Clinical medical policy defining prior authorization and medical necessity criteria for Kadcyla (ado-trastuzumab emtansine) across HER2-positive oncology indications including breast cancer, NSCLC, brain metastases, head & neck and salivary gland tumors for Anthem members.
Updated NCCN recommendation for use in brain metastases with HER2-positive breast cancer to allow combination with neratinib and clarified use timing.
Updated NCCN recommendation for use in NSCLC to ensure individuals are not switching between drugs with similar mechanisms of action at progression.
Clarified trastuzumab biosimilars are considered equivalent where referenced in prior anti-HER2 therapy requirements.
Coding range for breast cancer ICD-10 codes expanded (added C50.A0-C50.A2 to existing range); removal of C79.81.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.